2月24日，浙江省医保局发布了《关于召开两类医用耗材省际联盟集中带量采购工作培训的通知》，此次培训内容涉及心脏起搏类、周围血管介入微导管 两类耗材省际联盟集采，培训时间为2026年3月2日。 本次集采的耗材品种为2大类高值耗材：心脏起搏类和周围血管介入微导管类医用耗材，两类耗材的采购文件已于近日下发。 其中，周围血管介入微导管类耗材集采由北京、天津、河北、山西、内蒙古、辽宁、吉林、黑龙江、上海、江苏、浙江、安徽、福建、江西、湖北、湖 南、广西、海南、重庆、四川、贵州、云南、西藏、陕西、甘肃、青海、宁夏、新疆及新疆生产建设兵团等29个省市组成采购联盟。 采购主体覆盖酒泉市所有公立医院，其中包含基层医疗机构卫生单位以及军队医疗机构，采购周期为2年。 虽然执行时间还没最终敲定，但中选结果已出，降价落地只是时间问题。并且《通知》指出，本次结果公布后，不再接受申诉质疑。 两超大联盟启动！ 2026年耗材集采机制进一步优化 春节刚过，耗材集采就踩下油门。如果说酒泉的10类普耗是开胃菜，那浙江牵头启动的两大省际联盟，才是真正的硬菜。 该类别聚焦神经介入治疗微导管和外周血管介入微导管两类产品（不包括套装、特定功能输送微导管等 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [2][5] Core Insights - The medical consumables sector saw a weekly increase of 2.29%, outperforming the CSI 300 index by 0.14 percentage points [2][4] - The current PE (ttm) for the medical consumables sector is 35.38X, with a PB (lf) of 2.54X, indicating a slight increase in valuation metrics compared to the previous week [3][16] - Recent policy changes from the National Health Commission aim to enhance the capabilities of grassroots medical institutions, which is expected to drive demand for specialized medical equipment and consumables [4][19] - The initiation of centralized procurement for high-frequency electric knives across 29 provinces presents opportunities for domestic brands to gain market share [4][20][22] Summary by Sections Industry Performance - The medical consumables sector reported a weekly increase of 2.29%, with a current index value of 5840.56 points [2][8] - The sector's performance over the past 12 months shows a relative decline of 9% compared to the CSI 300 index [2] Valuation Metrics - The PE ratio for the medical consumables sector is currently at 35.38X, with a year-to-date maximum of 40.1X and a minimum of 28.88X [3][16] - The PB ratio stands at 2.54X, with a maximum of 2.92X and a minimum of 2.13X over the past year [3][18] Industry Dynamics and Announcements - The National Health Commission's new guidelines encourage grassroots medical institutions to upgrade from general to specialized departments, increasing the demand for specific medical consumables [4][19] - The centralized procurement initiative for high-frequency electric knives is expected to facilitate domestic brands' entry into mainstream hospitals, with a pricing mechanism that rewards product differentiation [4][20][22] Investment Recommendations - The report suggests focusing on leading companies with strong cost control and innovation capabilities, particularly those benefiting from domestic substitution and policy guidance in the rehabilitation and chronic disease management sectors [5][24] - Specific companies to watch include those with diverse product lines and high innovation in high-value consumables, such as electrophysiology and interventional products [5][24]

Core Viewpoint - Weigao Orthopedics (688161) plans to utilize 86.46 million yuan of unallocated fundraising from the "R&D Center Construction Project" to acquire a stake in Suzhou Jiesibai Medical Technology Co., Ltd. (referred to as "Jiesibai") and increase its capital, resulting in the company holding 55% of Jiesibai's shares and consolidating it into its financial statements [1] Group 1 - The acquisition will enhance Weigao's capabilities in minimally invasive orthopedic products and energy-based devices, aligning with the focus of its R&D Center [1] - Jiesibai specializes in spinal minimally invasive and sports medicine, possessing two major technology platforms in minimally invasive orthopedic and energy-based devices [1] - The collaboration is expected to strengthen Weigao's technological accumulation in high-frequency electric knives, surgical power systems, and ultrasonic bone knives, further enhancing its advantages in minimally invasive products such as spinal and arthroscopic surgical products [1]

Core Viewpoint - Weigao Orthopedics (688161.SH) plans to change the use of 86.46 million yuan of unutilized funds from its "R&D Center Construction Project" to acquire a stake in Suzhou Jiesibai Medical Technology Co., Ltd. and increase its capital, resulting in a 55% ownership stake in Jiesibai [1] Group 1: Company Acquisition - The company will invest 86.46 million yuan to acquire part of the equity of Jiesibai and increase its capital [1] - After the transaction, the company will hold a 55% stake in Jiesibai, which will be included in the consolidated financial statements [1] Group 2: Jiesibai Overview - Jiesibai focuses on minimally invasive spine and sports medicine, possessing two major technology platforms: orthopedic minimally invasive and active energy devices [1] - Key products include percutaneous spinal endoscopes, orthopedic joint endoscopes, ultrasonic bone knives, medical endoscope imaging systems, high-frequency electric knives, and various supporting instruments and consumables [1] - The company has strong R&D capabilities in the fields of minimally invasive orthopedic products and active energy products [1]

Core Viewpoint - Weigao Orthopedics (688161.SH) plans to change the use of 86.46 million yuan from its "R&D Center Construction Project" to acquire a stake in Suzhou Jiesibai Medical Technology Co., Ltd. and increase its capital, resulting in a 55% ownership stake in Jiesibai, which will be consolidated into its financial statements [1] Group 1: Financial Details - The company intends to invest 379.6255 million yuan in the "R&D Center Construction Project" [1] - The unused portion of the raised funds, amounting to 86.46 million yuan, will be redirected for the acquisition and capital increase [1] Group 2: Company Profile of Jiesibai - Jiesibai specializes in minimally invasive spine and sports medicine, with strong R&D capabilities in orthopedic minimally invasive products and active energy products [1] - The main products of Jiesibai include percutaneous spinal endoscopes, orthopedic joint endoscopes, ultrasonic bone knives, medical endoscopic imaging systems, high-frequency electric knives, and various supporting instruments and consumables [1]

Core Viewpoint - The article highlights the advancements in minimally invasive and precise treatment for gastrointestinal diseases at the Rongcheng People's Hospital Endoscopy Center, which has significantly improved early cancer detection rates and aims to enhance overall diagnostic capabilities in the region [1] Group 1: Technological Advancements - The Endoscopy Center was established in 2021 and is equipped with advanced technologies such as Olympus high-definition endoscopy systems, ERBE high-frequency electrosurgical devices, and Fujifilm ultrasound endoscopes [1] - The center performs approximately 12,000 gastrointestinal procedures annually, including 140 cases of ERCP and 80 cases of ESD, indicating a robust operational capacity [1] Group 2: Future Developments - The procurement process for small bowel endoscopes is currently underway, which will further enhance the center's ability to diagnose and treat gastrointestinal diseases comprehensively [1] - The center aims to establish a standardized training base over the next five years, leveraging expert resources from the Chinese Medical Education Association's Gastroenterology Endoscopy Committee to cultivate talent [1] Group 3: Strategic Goals - The strategic goal is to achieve "homogenization of endoscopic diagnosis and treatment" within county-level healthcare, ensuring that local populations have access to high-quality medical services equivalent to those provided by provincial hospitals [1]